Cerebral β-amyloid deposition predicts HIV-associated neurocognitive disorders in APOE ε4 carriers. - Wikidata - wikimedia - TriplyDB

Cerebral β-amyloid deposition predicts HIV-associated neurocognitive disorders in APOE ε4 carriers.

Cerebral β-amyloid deposition predicts HIV-associated neurocognitive disorders in APOE ε4 carriers.

http://www.wikidata.org/entity/Q36622848

about

Natural Products as Anti-HIV Agents and Role in HIV-Associated Neurocognitive Disorders (HAND): A Brief Overview Chronic inflammation and the role for cofactors (hepatitis C, drug abuse, antiretroviral drug toxicity, aging) in HAND persistence Genetic, transcriptomic, and epigenetic studies of HIV-associated neurocognitive disorder The Chronicity of HIV Infection Should Drive the Research Strategy of NeuroHIV Treatment Studies: A Critical Review Amyloid β: one of three danger-associated molecules that are secondary inducers of the proinflammatory cytokines that mediate Alzheimer's disease β-Amyloid1-42, HIV-1Ba-L (clade B) infection and drugs of abuse induced degeneration in human neuronal cells and protective effects of ashwagandha (Withania somnifera) and its constituent Withanolide A Cytomegalovirus and HIV: A Dangerous Pas de Deux The longitudinal and interactive effects of HIV status, stimulant use, and host genotype upon neurocognitive functioning.PET brain imaging in HIV-associated neurocognitive disorders (HAND) in the era of combination antiretroviral therapy.HIV-1 stimulates nuclear entry of amyloid beta via dynamin dependent EEA1 and TGF-β/Smad signaling.HIV protease inhibitor exposure predicts cerebral small vessel disease.Effects of APOE ε4, age, and HIV on glial metabolites and cognitive deficits Host genetic factors predisposing to HIV-associated neurocognitive disorder.Activation of TRPML1 clears intraneuronal Aβ in preclinical models of HIV infection.Ashwagandha (Withania somnifera) reverses β-amyloid1-42 induced toxicity in human neuronal cells: implications in HIV-associated neurocognitive disorders (HAND).No association between Apoε4 alleles, HIV infection, age, neuropsychological outcome, or death.Transcriptional profile of HIV-induced nuclear translocation of amyloid β in brain endothelial cells.Cerebrospinal fluid (CSF) CD8+ T-cells that express interferon-gamma contribute to HIV associated neurocognitive disorders (HAND)APOE ε4 moderates abnormal CSF-abeta-42 levels, while neurocognitive impairment is associated with abnormal CSF tau levels in HIV+ individuals - a cross-sectional observational study.Elevated rates of mild cognitive impairment in HIV disease.Interacting partners of macrophage-secreted cathepsin B contribute to HIV-induced neuronal apoptosis.Brain and liver pathology, amyloid deposition, and interferon responses among older HIV-positive patients in the late HAART era.The adaptive immune system restrains Alzheimer's disease pathogenesis by modulating microglial function.Accelerated epigenetic aging in brain is associated with pre-mortem HIV-associated neurocognitive disorders.Lipid Profiles and APOE4 Allele Impact Midlife Cognitive Decline in HIV-Infected Men on Antiretroviral Therapy.HIV associated neurocognitive disorders in the modern antiviral treatment era: prevalence, characteristics, biomarkers, and effects of treatment.Apolipoprotein E4 Suppresses Neuronal-Specific Gene Expression in Maturing Neuronal Progenitor Cells Exposed to HIV.An Overview of Human Immunodeficiency Virus Type 1-Associated Common Neurological Complications: Does Aging Pose a Challenge?Differentiating HIV-Associated Neurocognitive Disorders From Alzheimer's Disease: an Emerging Issue in Geriatric NeuroHIV.Fingolimod induces neuronal-specific gene expression with potential neuroprotective outcomes in maturing neuronal progenitor cells exposed to HIV.Microwave & magnetic proteomics of macrophages from patients with HIV-associated cognitive impairment.Multilevel analysis of neuropathogenesis of neurocognitive impairment in HIV.Plasma soluble CD163 is associated with postmortem brain pathology in human immunodeficiency virus infection.Extracellular vesicles of the blood-brain barrier: Role in the HIV-1 associated amyloid beta pathology.Soluble TLR2 and 4 concentrations in cerebrospinal fluid in HIV/SIV-related neuropathological conditions.ApoE ε4 Is Associated With Cognition, Brain Integrity, and Atrophy in HIV Over Age 60.Lifetime methamphetamine dependence is associated with cerebral microgliosis in HIV-1-infected adults.Molecular Mechanisms for Herpes Simplex Virus Type 1 Pathogenesis in Alzheimer's Disease.Molecular Mechanisms for Herpes Simplex Virus Type 1 Pathogenesis in Alzheimer’s Disease.Withaferin A Suppresses Beta Amyloid in APP Expressing Cells: Studies for Tat and Cocaine Associated Neurological Dysfunctions

P2860

Q26770401-48096330-734D-4951-BA01-07863D1F73C7 Q26825762-91468EBD-EF72-4B0F-820D-9A9DC319B7D5 Q26865707-BA6FAE17-CD4A-4670-AF83-FCB8EEB60820 Q28066725-6CE3DD3D-6B08-4A57-A57E-4FFC0786698F Q28384947-5A991DC7-02FF-46F4-8D30-BCE3B8C5F5AA Q28545117-2442C7D4-5DDD-49A7-AFE1-79F3F728F5BD Q30245376-C3D786BD-C0DD-404F-864B-577D9CBEC287 Q30410418-93254C41-4AAA-44AA-9628-1A82CF072000 Q31153188-E44ECC87-315E-46B1-8E9F-79AB85AB45B7 Q33604503-9C1CADEE-E0CD-48D6-AD42-74E062CFFE4D Q33807507-E03FE0A1-C93D-46E6-8950-539F8A6808D7 Q33961790-C834FC4F-7E26-464F-9640-E960E6E00919 Q34001122-991270EC-DE51-4075-911A-85C73E7E6281 Q34067393-D2388CBC-6696-4F94-A7A6-44931340A019 Q35023273-5888A838-E7F5-4D13-8095-BCFD8BBD78B8 Q35058529-15BF34BD-6DFC-426D-85A6-93BAEC8FE69F Q35072502-ED28D684-427D-4960-B6D1-2666B3E32E2A Q35125862-F8672BF7-AEEF-4873-AB29-563E9E658633 Q35276365-2C07B517-4829-4073-9847-30CC8392D538 Q36200027-1A7AE13D-8283-437F-B7E4-96F7EB74A91B Q36259524-91126DF6-5E7B-4B18-BC4D-931CC55872DC Q36284359-8F77AFA2-1B6E-479B-830B-A4474B907DBF Q36659056-91649BC9-648D-4318-976C-E318CD1CD117 Q36989549-FE000366-9128-4A2A-9EAD-48487D3C6A72 Q37284168-7446B9A9-CDAE-4307-9ED3-1C75F04E1F46 Q38223328-0CC718C9-2C6C-4CD9-88DF-484437DF1FF1 Q38435698-4097B67B-8568-47ED-9C74-46C872A71701 Q38628801-8A59E96E-2CDB-409E-B130-5FAA78CB529E Q38639562-E593D607-ACA9-4058-876F-9D1212D85D0A Q40039541-59413C38-D8F6-48EB-BF84-7B5856FFBA4A Q40107495-217002E6-D4D1-4F21-87ED-0EB6D1077920 Q40241936-23C4AEC0-7444-410A-A841-FEF0ED023389 Q40314419-128F2BFA-6A20-4C30-A912-FCE4D5C6BABA Q40389352-722C6022-0B39-4F50-92FC-767B8DEFBD16 Q40437527-95AEF44D-3D31-41B5-986B-EDCF3C39AB06 Q40481227-4F85375D-0FC3-4C55-9F53-1BE8F0375A92 Q40705923-74A2BBFF-BD7F-42D6-A511-D07C2E19001A Q51761118-1D0FD693-E7E0-417F-A64F-F78DCA252EAF Q55021072-F1B834A0-1F84-4CFF-908A-89E916E5A30A Q57821144-7CB8E905-390A-4B85-A9CB-7C8714EB7CBB

P2860

Cerebral β-amyloid deposition predicts HIV-associated neurocognitive disorders in APOE ε4 carriers.

http://www.wikidata.org/entity/Q36622848

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

2012年论文

@zh

2012年论文

@zh-cn

name

Cerebral β-amyloid deposition ...... disorders in APOE ε4 carriers.

@ast

Cerebral β-amyloid deposition ...... disorders in APOE ε4 carriers.

@en

type

label

Cerebral β-amyloid deposition ...... disorders in APOE ε4 carriers.

@ast

Cerebral β-amyloid deposition ...... disorders in APOE ε4 carriers.

@en

prefLabel

Cerebral β-amyloid deposition ...... disorders in APOE ε4 carriers.

@ast

Cerebral β-amyloid deposition ...... disorders in APOE ε4 carriers.

@en

P1433

Q36622848-AC8E389B-933A-426F-9170-E8FD6AE47BFD

P1476

Q36622848-938E0AF3-36D0-4140-8341-F54939B93B90

P2093

Q36622848-0B24C18C-FE25-49BF-8C9D-361CC7502C01

Q36622848-6AC74424-E460-42CD-8CAB-6AA12640EE8B

Q36622848-8B2356DF-4D6F-4317-9F5C-E09A81B84813

Q36622848-96ECBC7A-1AE8-4B3B-A2BA-038C459CA9E8

Q36622848-ABE3C4DB-0542-4DF5-90F6-CDBC8FA22D6B

Q36622848-C54EC3D0-BDF4-43BB-B6BB-D7056D69663D

Q36622848-CC7DFEAC-3A1A-45AB-9CA2-D4CCC247B083

Q36622848-D1FDBA4D-67A9-43D0-8073-66E1966B60D9

Q36622848-DA4DD676-3C1C-4963-8DED-0B7D0D04AD43

Q36622848-E2FB085C-18E9-4F4B-85A4-E2ED28A52D82

P2860

Q36622848-01D9992B-E195-41D2-A3B9-16E162AE33E4

Q36622848-02A15ABD-E1A5-47AF-8E5C-E8F17A5786D5

Q36622848-06B00B62-95EC-4F38-81DB-8B3EAE8422C7

Q36622848-0A011E2D-77B0-4796-9B41-0663573A69F8

Q36622848-0D0EC6FC-BEB3-4003-BCE7-3AADC9ADFDD6

Q36622848-11AE22EE-F7F7-47D1-9BC9-6AD109E707E5

Q36622848-156996CB-3D68-4030-839C-B7DAA66225EF

Q36622848-20902A84-2E4A-4477-9E78-856B0B2E66C7

Q36622848-20E4CA71-1C50-4D0F-B8A1-F581433AAC67

Q36622848-2655C0B4-8C84-49CE-A11C-61A7DC864506

P304

Q36622848-CC35AC18-0060-45F6-B21F-09471ED66905

P31

Q36622848-71059C90-ED7C-4D3A-A0B3-9CEF3CA3D879

P356

Q36622848-005252D8-A362-4867-B468-B243116359E7

P407

Q36622848-8ABCA6F9-CF6E-4138-9620-9DD75A9D6645

P433

Q36622848-218C80B0-A4A5-4DF8-BA34-0F3A89C16CE4

P478

Q36622848-039C52A6-DBC2-48AC-8F89-087D1DBC4E3F

P50

Q36622848-05505CCB-6D1A-4AD3-ADD1-B80C60D922FD

Q36622848-7EF94E04-E53E-467C-AEC2-8A8739D9A2E0

Q36622848-AEBB961F-DDBD-4866-8E87-C2DD57003548

Q36622848-B3F0AB05-C045-4871-BDBC-3E220FA5BF43

P577

Q36622848-E5A6820F-3126-4C1D-9719-7A80C5673FA4

P698

Q36622848-189499EE-17E0-4E7E-BD6B-2196620BDCFB

P932

Q36622848-EFE0ECE1-4101-4A54-8E44-13D1FE720780

P356

QAD.0B013E32835A117C

P1433

P1476

Cerebral β-amyloid deposition ...... disorders in APOE ε4 carriers.

@en

P2093

Andrew J Levine

http://www.w3.org/2001/XMLSchema#string

Anya Umlauf

http://www.w3.org/2001/XMLSchema#string

Ben Gouaux

http://www.w3.org/2001/XMLSchema#string

Benchawanna Soontornniyomkij

http://www.w3.org/2001/XMLSchema#string

Benjamin B Gelman

http://www.w3.org/2001/XMLSchema#string

Cristian L Achim

http://www.w3.org/2001/XMLSchema#string

David J Moore

http://www.w3.org/2001/XMLSchema#string

Elyse J Singer

http://www.w3.org/2001/XMLSchema#string

Erick T Tatro

http://www.w3.org/2001/XMLSchema#string

Mariana Cherner

http://www.w3.org/2001/XMLSchema#string

P2860

Apolipoprotein E, Dementia, and Cortical Deposition of β-Amyloid Protein

HIV-associated neurocognitive disorders before and during the era of combination antiretroviral therapy: differences in rates, nature, and predictors

Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families

Apolipoprotein E: far more than a lipid transport protein

Apolipoprotein (apo) E4 enhances HIV-1 cell entry in vitro, and the APOE epsilon4/epsilon4 genotype accelerates HIV disease progression

Amyloid and tau cerebrospinal fluid biomarkers in HIV infection.

Cerebrospinal fluid tau and ptau(181) increase with cortical amyloid deposition in cognitively normal individuals: implications for future clinical trials of Alzheimer's disease

APOE predicts amyloid-beta but not tau Alzheimer pathology in cognitively normal aging.

Neurovascular mechanisms and blood-brain barrier disorder in Alzheimer's disease.

An exploratory study of long-term neurocognitive outcomes following recovery from opportunistic brain infections in HIV+ adults.

P304

2327-2335

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1097/QAD.0B013E32835A117C

http://www.w3.org/2001/XMLSchema#string

P407

P433

18

http://www.w3.org/2001/XMLSchema#string

P478

26

http://www.w3.org/2001/XMLSchema#string

P50

Eliezer Masliah

Harry V Vinters

P577

2012-11-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23018443

http://www.w3.org/2001/XMLSchema#string

P932

3576852

http://www.w3.org/2001/XMLSchema#string